An ongoing Phase 1/2a trial exploring a type of engineered antibody — the anti-CTLA-4 probody BMS-986249 by CytomX Therapeutics — alone and in combination with Opdivo (nivolumab) in treating advanced solid tumors is expanding to include people with melanoma.
Archive | Clinical Trials
Phase 2 Trial of Probody-Opdivo Combo Expanding in Advanced Cancers
Posted in Melanoma News, Health Professionals, Clinical Trials
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
SHANGHAI, March 16, 2020 /PRNewswire/ — InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal […]
Posted in Melanoma News, Health Professionals, Clinical Trials
Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations
The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.
Posted in Melanoma News, Health Professionals, Clinical Trials
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Immune checkpoint blockade (ICB) has transformed melanoma treatment, but optimal sequencing of ICB and surgery for clinically evident nodal metastasis remains undefined.
Posted in Melanoma News, Health Professionals, Clinical Trials
